Mast cells control lung type 2 inflammation via prostaglandin E₂-driven soluble ST2

Area of Science:

• Immunology
• Respiratory Medicine
• Inflammation Research

Background:

• Severe asthma and sinus disease are linked to type 2 inflammation (T2I).
• Interleukin-33 (IL-33) signaling via its receptor ST2 mediates T2I.
• Soluble ST2 (sST2) limits T2I, but its regulation is poorly understood.

Purpose of the Study:

• To investigate the role of prostaglandin E2 (PGE2) in regulating sST2 production.
• To elucidate the mechanism by which PGE2 influences T2I.
• To understand the link between PGE2, sST2, and severe respiratory T2I.

Main Methods:

• Utilized PGE2-deficient mouse models.
• Assessed sST2 levels in serum and lung tissue.
• Investigated the role of mast cells (MCs) and E prostanoid (EP)2 receptors in sST2 production.
• Administered recombinant sST2 in mouse models.

Main Results:

• PGE2 deficiency led to reduced sST2 levels and exacerbated T2I in mice.
• PGE2 enhanced sST2 secretion from mast cells.
• Mice lacking mast cells, ST2 on mast cells, or EP2 receptors on mast cells showed decreased sST2 and increased T2I.
• Recombinant sST2 ameliorated T2I in mice with PGE2 deficiency or lacking ST2 on mast cells.

Conclusions:

• PGE2 drives sST2 production by mast cells, thereby suppressing T2I.
• This mechanism explains severe T2I in low PGE2 states.
• Targeting the PGE2-sST2-mast cell axis may offer therapeutic strategies for severe asthma and sinus disease.